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Dementia is a substantial and increasing public health concern. Despite decades of research, a cure or effective
preventative treatment for dementia remains elusive. We offer critical review of contemporary dementia research
and discuss potential reasons why progress in the field has not been as rapid as in other disciplines. We adopt a
broad approach in keeping with the broad nature of the topic. We cover the difficulties inherent in studying
dementia from 'bench' to 'bedside' to 'population'. We make particular reference to issues of operationalisation of
the dementia syndrome and our evolving understanding of dementia as a research 'outcome'. We discuss
contemporary 'hot topics' in dementia research methodology focussing on dementia models, pre-dementia states
and biomarkers. Recognising the importance of prospective epidemiological cohorts and large-scale clinical trials
we pay particular attention to these approaches and the challenges of generating results that have 'real world'
external validity. Based on our thoughts we end with suggestions for future dementia research. Our review is
designed to be critical but not unnecessarily negative. There is reason for cautious optimism in dementia research.
The recent G8 summit on dementia and subsequent establishment of the World Dementia Council are examples of
initiatives that reflect societal and political will to increase research efforts in dementia.Introduction
The scientific and lay press frequently remind us of the
changing global demographic. Increasing longevity should
be celebrated as a medical and public health success, but
with increasing age comes (currently) increasing prevalence
of age-associated diseases, including the dementias. The
evidence-based medicine movement has facilitated major
advances in our understanding and treatment of disease,
but progress has not been equally shared amongst diseases.
While cardiovascular disease research has yielded a wealth
of effective primary and secondary preventative treatments,
dementia remains less well understood with a paucity of ef-
fective treatments. This inequality in treatment options is
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unless otherwise stated.dementia is modest compared with that for cardiovascular
disease or cancer [1].
In this review we consider some of the limitations and
challenges of researching dementia. It would not be possible
to comprehensively describe the entire dementia research
field in a single review and we have chosen to focus on
those areas we feel are most pertinent to contemporary
clinicians and researchers. Recognising the difficulty of
studying a condition where diagnosis is 'clinical', we begin
by describing how we operationalise the dementia syn-
drome. We then review three 'hot topics' in dementia
research: (i) dementia models, (ii) biomarkers and (iii) 'pre-
dementia' states. We conclude with discussion of large-scale
studies, both observational cohorts and interventional trials.Operationalising dementia
What is dementia? A researcher’s perspective
A fundamental problem in dementia research has been
defining exactly what we are researching. Arguably, theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has led to compartmentalised thinking and research. As
a research 'outcome' dementia can be operationalised at
various levels. We have developed a nosological system
wherein dementia can be diagnosed as a syndrome and
further classified by presumed underlying disease (for
example Alzheimer’s) and this classification can be sub-
typed again (Alzheimer’s variants). Classification by the
clinical symptomatology, the neurohistopathology, char-
acteristics of the patient group ('pre-senile' dementia) or
site of predominant anatomical change ('subcortical') have
all been employed [2]. While many of these classifications
are now obsolete, new technologies, particularly dementia
'biomarkers', may foster a plethora of new research ter-
minologies and labels [3].
Dementia remains a clinical diagnosis and this diag-
nosis is usually made using standardised classification
systems such as the American Psychiatric Association
Diagnostic and Statistical Manual of Mental Disorders
(DSM) or the World Health Organization International
Classification of Disease (ICD) [4,5]. These lexicons
bring a degree of clarity but it is worth noting that there
are differences in their approaches, and studies compa-
ring contemporaneous assessment with ICD and DSM
reveal potential disagreements in classification [6]. Nei-
ther system is superior to the other and both have been
criticised for their reliance on memory impairment to
make a diagnosis and their focus on defining exclusive
disease subtypes and their use of criteria designed to
capture disease only once it is clinically obvious and other
conditions have been fully excluded [6].
A revision of DSM (DSM-V) was published in May
2013 and revision of ICD (ICD-II) is anticipated [4].
DSM-V has moved from a focus on memory and has
redefined 'dementia' as 'neurocognitive disorder' with
qualifiers of 'major' or 'minor' disorder. Major neurocog-
nitive disorder is not synonymous with 'dementia' as
previously described and we will have to be mindful of
this when interpreting and comparing data from studies
that use different iterations of DSM. Classification sys-
tem content continues to lag behind improvements in
our understanding of natural history and pathogenesis.
In the rapidly evolving landscape of contemporary
dementia research, more frequent revision of diagnostic
classification may become necessary.
Research has historically concerned dementia at the later
stages, when definitive diagnosis can be made. Develop-
ments in imaging and molecular medicine are beginning to
redefine our understanding of the natural history of demen-
tia and this may in turn influence operational definitions of
dementia states. The current understanding of (certain
forms of) dementia progression describes neuropathological
changes associated with development of dementia that may
precede symptomatic disease by decades, cognitive changenot yet sufficient to warrant a dementia label and then a
state of overt dementia with progressive clinical severity [7]
(Figure 1). For practical reasons we arbitrarily define these
clinical stages, but the reality is of a continuum with no
clear temporal delineation between stages. In fact some may
reach a stage of cognitive impairment and not progress fur-
ther, while others may even show reversion to 'normal' cog-
nition. The ongoing debate as to where in the pathway
research resources should be targeted is a reminder of our
limited understanding of the dementia progression pathway.
What about dementia subtypes?
The traditional approach to dementia has been to define
a disease syndrome and then try to describe the under-
lying disease state. The diseases that cause dementia are
defined in terms of classical autopsy-based neuropathol-
ogy, yet we attempt to assign these labels in life through
recognition of certain phenotypic patterns. The com-
monest cause of dementia in community dwelling older
adults is Alzheimer’s disease (AD). AD research has ac-
cordingly tended to dominate the dementia landscape.
Indeed many of the major scientific journals in dementia
research have the term 'Alzheimer’s' in their title. To
maintain scientific purity a focus of traditional dementia
research has been around separating AD dementia from
other dementia types.
Improvements in our understanding of later life
dementia cause us to question the utility and validity of
this rigid classification-based approach. Risk factors for
AD and vascular dementia are shared [8] and the major-
ity of dementia in older age is 'mixed' with varying
degrees of vascular, amyloid and other pathologies [9].
In older adults correlation between clinical classification
and the predominant neuropathology seen at autopsy is
poor [10]. If the goal is to describe or target dementia at
the population level, then strict classification-based
inclusion/exclusion criteria may give data with limited
external validity [11].
While at a population level treating dementia as a sin-
gle entity may be appropriate, no-one would argue that
we should stop trying to classify dementia completely.
Indeed the increasing interest in stratified medicine would
argue for greater pathological classification. We must also
be mindful of not extrapolating research from a specific
dementia group and applying the findings to the entire
syndrome, the so-called Alzheimerisation of dementia.
These apparently opposite approaches can exist together
and there are examples of successful research paradigms
where conditions have been assessed both as a syndrome
and as individual disease groups. An example of this
would be the field of stroke research; important bodies
of work around small vessel disease stroke, intracere-
bral haemorrhage and cardioembolic stroke are all avail-
able, while large cohorts and trials have studied the stroke
unselected older adults
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Figure 1 The theory and reality of contemporary dementia research paradigms. (a) An 'ideal' model, wherein older adults with early
biomarker-detected changes of dementia can be selected and this cohort then progresses through a stage of 'cognitive impairment non-
dementia' (CIND) with eventual overt dementia of a particular pathological subtype. (b) A more complex situation that is closer to the 'real world'
of dementia research, wherein predictive accuracy of biomarkers is not 100% sensitive or specific, CIND to dementia conversion is neither
predictable nor inevitable and the final syndrome of dementia is often a mix of underlying pathologies. CSF, cerebrospinal fluid; MCI, mild
cognitive impairment.
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practice.How do we quantify dementia in research?
A consistent feature of dementia research is the incon-
sistency in how we measure the syndrome of interest.
Dichotomous 'dementia' versus 'no dementia' outcomes
have utility but can be methodologically inefficient with
limited precision and responsiveness to change [12]. For
describing dementia incidence or prevalence, there is a
trade-off between the validity of the case ascertainment
and the time and effort required. A gold standard of
expert clinical diagnosis requires availability of expert
assessors and access to appropriate investigations and
ideally repeats assessment to document change over
time. This approach is only possible at the individual
patient or small scale study level. In contrast, using
routinely recorded data, such as is held in primary care
registries, can allow for relatively quick assessment of
whole populations for those with a label of dementia.
However, the resulting data will be less robust and in
particular there are likely to be numerous 'false nega-
tives' [13] (Figure 2). Even within a rubric of clinical
diagnosis, there may be heterogeneity in the dementia
assessment employed. A distinction could be made be-
tween the dementia diagnosis made in routine clinical
practice and the diagnosis made as part of a research
study, where the clinical study can potentially make
use of expert adjudication panels and comprehensive
ancillary investigations to give a robust diagnostic label
while in routine care there may be more limited accessVALIDITY
TIME / EFFORT
REGISTRY 
DATA
COGNITIVE 
SCREENS
NEUROPSYCH 
BATTERY
CLINICAL 
DIAGNOSIS
NEURO 
PATHOLOGY
Figure 2 Methods of assigning dementia diagnosis for clinical
research. Differing methods of assigning the dementia outcome are
described in terms of the time and effort required to make the
diagnosis (x-axis) and the external validity of that diagnosis (y-axis).
The positions are illustrative only and designed to show the 'trade
off' between effort and validity. In assigning validity we assume
that expert clinical assessment is the reference standard; hence,
neuropathological assessment requires substantial time/effort but
validity is relatively low.to supplementary tests and any diagnostic label may be
more nuanced.
Various approaches to describing cognitive change as
a quantitative variable have been described, all with
vocal proponents [14]. Using some form of neuropsy-
chological assessment to quantify cognitive impairment
allows standardised assessment that does not necessar-
ily require lengthy 'expert' input and gives a numerical
output that can be used for analysis. An example of a
prevalent assessment tool is Folstein’s Mini-Mental
State Examination. This short, direct test of various
cognitive domains has been used in seminal dementia
studies but has a number of well documented limita-
tions [15] (Figure 3).
Many other cognitive assessments are available with
little guidance on the preferred tool(s). Even in a rela-
tively niche area such as post-stroke cognitive assess-
ment, around 300 different cognitive assessment tools
have been used in research and 45 different tools used in
clinical practice [16,17]. This substantial heterogeneity
complicates attempts at meaningful comparisons across
studies and effectively precludes pooled analyses of study
results without substantial efforts to harmonize and
co-calibrate the cognitive measures.
Choice of cognitive assessment tool for research should
be guided by the properties of that tool and the purpose
of the testing. Ferris and colleagues [18] described the
ideal cognitive test, although this ideal is a theoretical
construct and no existing tool is 'perfect' (Figure 3).
There is a literature describing properties of cognitive
assessment tools [19] and efforts to synthesize the evi-
dence will hopefully bring greater clarity and consistency
to the field [20].
Regulatory guidance for trials of pharmacological in-
tervention in dementia suggests complementary approa-
ches to cognitive assessment, using a performance-based
measure of cognition and an independent clinician-rated
measure of global disease severity [21]. The use of global
measures was introduced to ensure that any change is
clinically 'meaningful' assuming that important change
will be apparent to the assessing clinician [22].
The dementia assessment is not only a cognitive
assessment. Dementia is a state of cognitive decline
sufficient to cause functional problems; thus, describing
function is a critical component. As with cognition, func-
tional assessment is challenging, particularly in an inter-
national, cross-cultural context. Further discussion of the
challenges of functional assessment is given in the section
on 'pre-dementia' states.
All the above assumes the biomedical perspective. Social
and psychological sciences argue that these measures are
overly reductionist and fail to capture the complex reality
of dementia as experienced by those with the condition
and their care-givers [23].
Desirable Property MMSE
Samples the full range of relevant cognitive 
functions
No (poor at describing executive functions 
amongst others)
Sensitive to deficits of ageing and dementia No (poor at determining Mild Cognitive 
Impairment)
Sensitive to longitudinal change No (poor responsiveness over short follow 
up periods)
Difficulty range appropriate to the severity 
of dementia in patient sample
No (problems with cultural and educational 
influences)
Equivalent forms for repeated 
administration 
No
Reasonable duration  (less than one hour) Yes (around 20 minutes assessment time)
Sensitive to treatment effects ? (although has been used in many seminal 
dementia RCTs)
Good reliability Yes (inter-observer and internal reliability 
both good) 
Good validity (in relation to pathology and 
activities of daily living)
? (association with function / activities of 
daily living not well described)
Figure 3 Properties of cognitive assessment tools. The first column describes the properties of an 'ideal' cognitive assessment tool (Ferris)
and the second column describes a popular assessment tool (Folstein’s Mini-Mental State Examination; MMSE) against these desired properties.
RCT, randomised controlled trial.
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Dementia 'models' for research
Dementia is predominantly a disease of later life with a
pathogenesis that may span decades. Thus, clinical stud-
ies may require protracted follow-up to assess outcomes
of interest. One could argue that the focus should be un-
selected older adults. However, older adults bring inher-
ent 'noise' in terms of comorbidity, frailty, polypharmacy
and so on, as well as the problem of attrition due to
death for non-dementia causes. Conversely, if we restrict
studies to 'healthy' adults, then results have limited ex-
ternal validity. This dilemma is not unique to dementia;
older adults with frailty or comorbidity are underre-
presented in many studies and evidence-based guidelines
may have limited relevance to 'real world' populations
[24]. This challenge does not preclude meaningful re-
search but emphasises a point that we will repeat in other
sections of this review: we can only progress dementia re-
search with cross-disciplinary collaboration that draws on
expertise from geriatric medicine, neurology, psychiatry,
psychology and other relevant fields. In the meantime
more efficient methods of studying dementia are clinically
and economically attractive. Unfortunately, dementia mo-
dels currently available are problematic.
Researchers have used human phenotypic 'extremes' to
study dementia - examples include the exclusively amyloid
pathology that results from mutations in the APP and
PSEN1/2 genes and the monogenic disease CADASIL
(cerebral autosomal dominant arteriopathy with subcor-
tical infarcts and leukoencephalopathy) for vascular de-
mentia [25]. Inherited dementias can give interesting
information, but the relevance of these pure pathologicalstates to sporadic dementia is at best limited. More com-
mon genetic variants can be employed to 'enrich' study
samples (for example, the A4 study currently recruiting
in North America). Genetic association studies have re-
vealed a wealth of potential dementia risk markers but
the effect of individual variants is often modest and it
has been argued that a genotyping approach may be no
more useful than a simple description of 'family history
of dementia' [26].
Transgenic animal models of various pathological
dementia subtypes have been described [27]. Translation
of promising results from mouse to man has often yielded
disappointing results [28]. Critical reviews of animal-based
dementia work are available; for example, the Collabora-
tive Approach to Meta-Analysis and Review of Animal
Data from Experimental Studies (CAMARDES) group
offer a critique of animal research in neurological disease
and suggestions for improved conduct and reporting.
They highlight recurring methodological limitations in
animal research that mirror those seen in clinical stud-
ies, including non-blinding, lack of randomisation and
publication bias [28]. Many of the problems in moving
from bench to bedside relate to the external validity of
the animal model employed. This is not solely a reflec-
tion of the increased complexity of the human brain
compared with the mouse brain. As discussed, demen-
tia usually happens as a result of mixed pathologies and
in the context of a host of confounders that are difficult
to simulate in the laboratory, including ageing, physical
frailty and premorbid education.
Dementia is a progressive condition and an attractive ap-
proach is to use statistical models to describe trajectories
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effects) models are commonly used in dementia research.
These approaches account for the auto-correlated nature
of data generated from longitudinal studies and estimate
average and individual trajectories using all available data
[29]. Estimates of the heterogeneity of individual trajector-
ies about the average trajectory are a key output of these
models as they inform about individual differences in the
evolution of disease. These models are highly flexible,
as either parametric or non-parametric versions may be
employed to describe non-standard trajectory shapes.
However, there are limitations; although data from
individuals with incomplete follow-up contribute to the
model, missing observations are assumed to be random,
an assumption implausible in the context of dementia
where differential dropout and mortality operate. Sec-
ondly, results may be sensitive to features of the data
and study design, such as ceiling and floor effects and sep-
aration of data collection waves. Thirdly, unless explicitly
separated, model estimates may represent a compound of
within and between individual sources of information
[30]. Extensions of standard formulations of latent growth
models (such as shared random effects models for mis-
sing data or Tobit models to account for ceiling/floor
effects) have been proposed, although their application
is not widespread [31].
An important aspect of modelling dementia-related
trajectories is the determination of the optimal time
metric to best describe temporal changes of the process
of interest. Intuitively, age may be considered as the nat-
ural metric to model change. A process-based approach
where outcomes are modelled as a function of distance
to the event that is most associated with the changes ob-
served (for example, time to dementia diagnosis) has0
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Figure 4 Modelling cognitive trajectory. (a) Comparing time to demen
Examination (MMSE) trajectories of a random sample of Origins of Varian
age and dementia diagnosis. As an illustration of how heterogeneity of trajec
approach, MMSE scores of a random sample of participants plotted as a
(b) Graphical illustration of a change point model. A schematic represe
the broken stick model [58].been shown to result in a reduction of residual variance
estimates and better fitting models [32] (Figure 4a). Al-
though process-based models result in better statistical
fit, results may be hampered by the availability of accur-
ate information about diagnosis. Change-point models
(sometimes also called broken stick models) are a par-
ameterisation of latent growth models that describe pro-
cesses that occur in two phases with an abrupt change
between them (Figure 4b). These models have been used
in dementia research to estimate the onset of accelerated
decline and are of particular interest to quantify change
in rate of decline before and after diagnosis and identify
risk factors that may differently affect the distinct phases
of the disease and factors that may be associated with a
delayed onset. Most applications of change point models
have been estimated under the strong assumption of a
common change point across individuals, although using
Bayesian estimation techniques (as opposed to maximum
likelihood estimation) random change point models have
also been considered to estimate individual change points
in preclinical dementia. Extensions to multivariate formu-
lations of change point models have been employed to
identify the temporal ordering of change [32] and models
that assume a smooth, rather than an abrupt, transition
have also been developed although not yet applied in
dementia research [33].
'Pre-dementia' states and research
Accepting the current view of AD dementia progression,
between asymptomatic pathological change and overt
disease there may be a period of more subtle cognitive
change not sufficient to meet diagnostic criteria for the
dementia syndrome. This transitional state has been given
many names, including mild cognitive impairment and5 10
iagnosis
b
tia and age to describe cognitive trajectories. Mini-Mental State
ce in the Oldest-Old Twin Study participants plotted as a function of
tories is reduced when scores are modelled using a process-based
function of age and time to dementia diagnosis are depicted [57].
ntation of the typical change point model trajectory as assumed in
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scribes the functional decline of major neurocognitive dis-
order as ‘sufficient to interfere with independence’. Thus,
the defining difference between CIND and established
dementia is in functional ability, with social and occu-
pational function preserved in CIND but impaired in
dementia. Functional assessment in dementia is fraught
with numerous challenges. Traditionally, we have used
care-giver-based informant assessments. These tools
are open to bias from care-givers’ mood and sense of
burden and many commonly used scales only provide a
snapshot of functional impairment. Functional assess-
ment scales used in other areas of elderly care (for
example, stroke research) may have some utility that
could be applied in dementia research [34].
The differentiation of CIND from dementia states is
crucial to research. Individuals with 'pre-dementia' are a
target population for studies of novel prognostic and
therapeutic interventions as this group theoretically of-
fers a window of intervention opportunity before overt
and irreversible cognitive change occurs. Recognising
the therapeutic potential of early intervention there are
currently around 124 registered trials of investigational
pharmacological agents in mild cognitive impairment/
CIND [35]. The US Food and Drug Administration man-
dates that conversion to dementia be used as study
endpoint in treatment trials and in studies to validate
biomarkers.
There are problems with the CIND conversion re-
search paradigm. There is limited guidance on what
constitutes CIND, particularly with regard to assessment
of function. There is no consensus on which scales to
use to measure functional ability or indeed what level of
activity limitation is sufficient to merit a dementia label.
As a result, CIND misclassification is prevalent in clinical
trials with up to a third of participants enrolled as CIND
misclassified and many already meeting criteria for de-
mentia [36]. The erroneous inclusion of those who have
early dementia into a CIND trial or failure to detect
progression to functional impairment and dementia will
substantially reduce trial power [37].
Temporal progression to established dementia is un-
predictable and not inevitable (Figure 1). Annual rates
for conversion of mild cognitive impairment to dementia
of around 10% are quoted but meta-analysis suggests
lower conversion over longer follow-up periods [38]. The
study sampling frame may be relevant, with community
recruited samples displaying much lower conversion rates
than clinical samples [38]. 'Reversion' from CIND to states
of normal cognition for age is also possible and further
complicates the field as most models assume an irrevoc-
ability to dementia progression. The limitations of the
clinical CIND definition led to proposals to enhance the
process through use of biomarkers [3]. However, theseproposals were lacking a strong empirical base [39] and
early evidence suggests that biomarkers may not provide
the hoped for improvement in accuracy [40].
What is the role of biomarkers in research?
Biomarkers are defined as characteristics that can be
objectively measured and used to evaluate biological
processes (normal or pathological) as part of a diagnos-
tic/prognostic evaluation or as indicator of response to
intervention. Neuroimaging and tissue (mostly cerebro-
spinal fluid) based biomarkers have been described that
may give an indication of early neuropathological change
suggestive of future dementia [39,40]. In a relatively short
time these biomarkers have been incorporated into diag-
nostic criteria and have been proposed as a novel method
to improve patient selection for dementia research. An
amyloid positron emission tomography ligand has been
licensed on the basis of its utility in excluding a diagnosis
of AD and the European Medicines Agency has supported
the use of certain markers for studies of prodromal AD.
There is a concern that biomarkers are increasingly used
in routine clinical work, a practice not supported currently
by any consensus clinical guidelines [41].
Two potential roles for biomarkers in dementia studies
have been described. Using biomarker data as a surro-
gate outcome measure is intuitively attractive as the
biomarker may offer early or more precise assessment of
between-group differences. However, we must be mind-
ful of high profile examples where positive trial data
based on biomarker surrogates did not translate into
meaningful clinical efficacy [42]. Biomarkers may also be
used to define populations at risk of dementia and so
'enrich' study populations [3] as well as acting as inter-
mediary phenotypes to decide on a drug’s continuation in
a trial aimed at showing clinical benefit. This approach
is at the core of the proposed Innovative Medicines
Initiative-European Prevention of Alzheimer’s Dementia
(IMI-EPAD) project.
We must be cautious in our enthusiasm, as there is
still much we do not know regarding dementia bio-
markers. The prognostic accuracy of biomarkers is sub-
stantially attenuated in older age; the proposed stepwise
progression from biomarker change to dementia is not
always apparent and time course is highly variable and
there is not always a clear biological gradient between
biomarker burden [41,43]. Existing statistical models
employed to assess how changes in biomarkers impact
on cognitive function are limited and need further devel-
opment and the historic lack of standardisation in both
sampling and analysis makes attempts at post hoc data
harmonisation challenging. There are also ethical and
feasibility issues. At present most biomarkers require
detailed neuroimaging or invasive tissue sampling. Given
the uncertainty around the 'meaning' of biomarkers, we
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disclosure in asymptomatic mid-life adults.
Large scale studies
Epidemiological studies in dementia?
The study of dementia epidemiology has presented several
challenges, some specific to dementia and some common
to other diseases.
A theme of dementia research has been looking to
define modifiable risk factors that may in turn prove to
be targets for intervention. Dementia, like many com-
mon non-communicable diseases, is the end result of a
complex interplay of genetic, lifestyle, clinical and
environmental factors. Given the multifactorial nature
of dementia, the strength of association for any one risk
factor is likely to be modest and very large populations
may be required to detect meaningful signals [44]. Some
have argued that it is overly simplistic to suppose that a
single factor will be responsible for a substantial propor-
tion of older age cognitive decline and researchers should
focus on identifying groups of interrelated/interacting
factors that are potentially causal or protective. A better
understanding of the frequency of risk factors in the
community should influence public health policy [45].
If we accept the current model of dementia with its
long latent period, it is difficult to define an ideal time to
begin study. Assessing late in the disease process may
miss opportunities, while assessing very early will require
follow-up periods that are not feasible using current study
methods. There are few large prospective studies that offer
follow-up from mid-life or younger though several have
recently initiated. Studying associations at various time
points in the dementia pathway is important as the role
of certain 'risk factors' may change as disease progres-
ses [46]. Novel programmes seek to develop complex
mid-life models associating risks with disease manifest-
ation and longer term clinical and cognitive outcomes
[46,47]. This focus on mid-life risk and dementia was
highlighted in the recent Blackfriar’s Consensus on Pro-
moting Brain Health [48].
Dementia and other non-communicable diseases share
many risk factors, not least of which is older age itself.
This may cause problems of competing risk where those
with potential to develop dementia die of other diseases
before cognitive decline is manifest. Another challenge
of studying a multifactorial disease with a long 'latent'
period is that the environmental context may change
over the period of study. As an example, the last few de-
cades have seen substantial changes in population levels
of education. Education can impact on dementia expres-
sion and current dementia incidence and prevalence
figures for older adults (based on educational and social
norms of the first half of the 20th century) may not
extrapolate to the future [49].As there is a ready supply of 'substrate', many demen-
tia studies have been conducted in the memory clinics
or wards of academic centres with a research interest in
dementia. The external validity of these cohorts is ques-
tionable. For longitudinal studies where patients are re-
cruited in specialist centres there needs to be robust links
with community and primary care for follow-up. Recent
European initiatives have sought to ‘re-purpose’ observa-
tional cohorts and develop community-based registers of
patients. The creation of such ‘readiness cohorts’ for trials
is one of the primary activities in the creation of the UK
Dementia Platform [50].
The ideal would be to study dementia using a repre-
sentative sample and a life course perspective. This is
potentially challenging and costly but not impossible.
There are examples of high quality, longer term prospect-
ive studies that are helping improve our understanding
of dementia - the Medical Research Council Cognitive
Function and Ageing Study is an exemplar [48]. Such
approaches require considerable investment to set up and
run. To maximise the potential return on this investment
there needs to be early consideration of data storage and
data linkage (mindful of data sharing and privacy con-
cerns) to external data sources such as electronic patient
records as well as to other relevant cohort databases,
an approach being taken in the Innovative Medicines
Initiative European Medical Information Framework
(IMI EMIF-AD) project [51].
Clinical trials in dementia
The ultimate goal of much of the research activity in de-
mentia is to develop interventions for 'treatment' or even
'cure'. The classical bench to bedside paradigm has been
disappointing in dementia. There is a long list of pu-
tative dementia treatment compounds with favourable
pre-clinical and early phase trial data that have been neu-
tral or even potentially harmful when assessed in phase III
studies [28].
The 'gold standard' for testing efficacy is the prospect-
ive, blinded, randomised controlled trial (RCT). Regula-
tory authorities took an early interest in dementia RCTs
and proposed a framework for assessment that is still
used today. Thus, dementia treatment RCTs have histo-
rically been fairly robust, but there may still be scope to
improve. Indeed there is a plausible argument that the
traditional single intervention RCT paradigm is not suited
to a complex multifactorial condition such as dementia
[46]. An issue specific to studies looking at later stages of
dementia is around consent to randomisation/interven-
tion. The complexity of contemporary dementia research
interventions can make informed consent challenging
even for patients with no cognitive issues. The consent,
recruitment and retention of patients with progressive
cognitive decline is problematic and further complicated
Note: This article is part of a series on The impact of acute and
chronic medical disorders on accelerated cognitive decline’, edited
by Carol Brayne and Daniel Davis. Other articles in this series can
be found at http://alres.com/series/medicaldisorders.
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Large scale, international RCTs are an expensive en-
deavour, with number of participants recruited being a
major factor in total cost. Expectations of treatment
effects from previous RCTs in dementia may have been
overly optimistic with possibility of type II statistical
error. Given the prevalence and disability associated with
dementia, even modest treatment effects many still be
important at a population level [26]. Data from other
neurological diseases suggest that optimising basic as-
pects of study process, such as improving classification
of outcomes, can have a substantial impact on required
sample size and ultimately cost of the study [37].
As with the 'life course' epidemiology studies discussed
previously, the cost of multicentre RCTs must be balanced
by efforts to maximise added value. The robust pheno-
typing and outcomes assessment of RCTs provides a data
resource that may be used for testing future novel hypoth-
esis. Collating anonymised, individual patient level data
across several such RCTs in a single resource designed for
future research has been demonstrated to have feasibility
in the field of cerebrovascular medicine [52,53]. In both
RCTs and prospective cohorts, collecting baseline and
follow-up samples to create a 'biobank' of tissue, imaging
and genetic materials as well as clinical outcome data with
broad consent that allows for future research and sharing
will increase the potential research utility beyond the pri-
mary aims of the original study. If participants give con-
sent for neuropathology, the research potential increases
further still. In all of this, consideration must be made to
'future-proofing' the data so that data are standardised to
allow harmonization with data from other resources.
Data from 'non-memory' RCTs can be used to progress
the dementia research agenda. High profile examples
from North America include the Framingham Heart
Study and the Honolulu Asia Aging Study, both of which
added cognition-based analyses to the existing cardiovas-
cular data [54]. Contemporaneous dementia assessment of
a population with detailed historical phenotyping has
allowed exploration of mid-life risk factors with later life
cognitive decline.
Greater harmonisation and a culture of sharing experi-
ence and best practice in dementia treatment and pre-
vention trials may help progress the dementia research
agenda with specific consensus statements appearing
[55] and the creation of conduct and reporting guidance
specific to dementia studies [56].
Conclusion
A dementia 'cure' remains elusive. One could speculate
that problems with trial design, endpoint definitions and
analysis may be contributory. However, we should avoid
research nihilism; there has been substantial advance inour understanding of dementia and as we develop new
techniques and technologies there is cause for cautious
optimism. Based on the discussion in this review we offer
some pointers for future dementia research initiatives.
Studies of dementia should recognise the potential
disconnection between a pure pathological state and the
clinical syndrome of late life dementia. We must be mind-
ful of extrapolating results for 'focussed' samples to an un-
selected all-cause dementia population.
Inconsistency in choice and reporting of outcome
measures is problematic. Based on evidence of test prop-
erties, we should look to build a core set of standardised
outcomes that can be supplemented by study-specific
measures. Where there is guidance on best practice in
reporting studies we should follow this.
Although advanced statistical models have been de-
veloped and applied to describe trajectories of cognitive
change, model assumptions and features of the data and
study designs need to be accounted for when imple-
menting these models in dementia research. Further col-
laboration between methodologists and clinicians should
be encouraged for the development of models that fully
consider the complexities of dementia studies.
Biomarkers potentially have an important role in
patient selection or as study outcome; however, the rele-
vance and utility of these tests in an unselected older
adult cohort is still to be described. Innovative study
designs will be required to capture the complexity of
dementia-related declines/biomarker changes and life-
style factors associated with these changes.
The complexity of dementia requires an international
collaborative approach, and examples of such efforts are
available [46,54]. This will be particularly important to
allow adequately powered phase III trials of prevention
or intervention.Abbreviations
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